Cargando…

Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics

Mycobacterium tuberculosis (M. tuberculosis) is considered innately resistant to β-lactam antibiotics. However, there is evidence that susceptibility to β-lactam antibiotics in combination with β–lactamase inhibitors is variable among clinical isolates, and these may present therapeutic options for...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Keira A., El-Hay, Tal, Wyres, Kelly L., Weissbrod, Omer, Munsamy, Vanisha, Yanover, Chen, Aharonov, Ranit, Shaham, Oded, Conway, Thomas C., Goldschmidt, Yaara, Bishai, William R., Pym, Alexander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972527/
https://www.ncbi.nlm.nih.gov/pubmed/27333036
http://dx.doi.org/10.1016/j.ebiom.2016.05.041
_version_ 1782446258745507840
author Cohen, Keira A.
El-Hay, Tal
Wyres, Kelly L.
Weissbrod, Omer
Munsamy, Vanisha
Yanover, Chen
Aharonov, Ranit
Shaham, Oded
Conway, Thomas C.
Goldschmidt, Yaara
Bishai, William R.
Pym, Alexander S.
author_facet Cohen, Keira A.
El-Hay, Tal
Wyres, Kelly L.
Weissbrod, Omer
Munsamy, Vanisha
Yanover, Chen
Aharonov, Ranit
Shaham, Oded
Conway, Thomas C.
Goldschmidt, Yaara
Bishai, William R.
Pym, Alexander S.
author_sort Cohen, Keira A.
collection PubMed
description Mycobacterium tuberculosis (M. tuberculosis) is considered innately resistant to β-lactam antibiotics. However, there is evidence that susceptibility to β-lactam antibiotics in combination with β–lactamase inhibitors is variable among clinical isolates, and these may present therapeutic options for drug-resistant cases. Here we report our investigation of susceptibility to β-lactam/β–lactamase inhibitor combinations among clinical isolates of M. tuberculosis, and the use of comparative genomics to understand the observed heterogeneity in susceptibility. Eighty-nine South African clinical isolates of varying first and second-line drug susceptibility patterns and two reference strains of M. tuberculosis underwent minimum inhibitory concentration (MIC) determination to two β-lactams: amoxicillin and meropenem, both alone and in combination with clavulanate, a β–lactamase inhibitor. 41/91 (45%) of tested isolates were found to be hypersusceptible to amoxicillin/clavulanate relative to reference strains, including 14/24 (58%) of multiple drug-resistant (MDR) and 22/38 (58%) of extensively drug-resistant (XDR) isolates. Genome-wide polymorphisms identified using whole-genome sequencing were used in a phylogenetically-aware linear mixed model to identify polymorphisms associated with amoxicillin/clavulanate susceptibility. Susceptibility to amoxicillin/clavulanate was over-represented among isolates within a specific clade (LAM4), in particular among XDR strains. Twelve sets of polymorphisms were identified as putative markers of amoxicillin/clavulanate susceptibility, five of which were confined solely to LAM4. Within the LAM4 clade, ‘paradoxical hypersusceptibility’ to amoxicillin/clavulanate has evolved in parallel to first and second-line drug resistance. Given the high prevalence of LAM4 among XDR TB in South Africa, our data support an expanded role for β-lactam/β-lactamase inhibitor combinations for treatment of drug-resistant M. tuberculosis.
format Online
Article
Text
id pubmed-4972527
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49725272016-08-10 Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics Cohen, Keira A. El-Hay, Tal Wyres, Kelly L. Weissbrod, Omer Munsamy, Vanisha Yanover, Chen Aharonov, Ranit Shaham, Oded Conway, Thomas C. Goldschmidt, Yaara Bishai, William R. Pym, Alexander S. EBioMedicine Research Paper Mycobacterium tuberculosis (M. tuberculosis) is considered innately resistant to β-lactam antibiotics. However, there is evidence that susceptibility to β-lactam antibiotics in combination with β–lactamase inhibitors is variable among clinical isolates, and these may present therapeutic options for drug-resistant cases. Here we report our investigation of susceptibility to β-lactam/β–lactamase inhibitor combinations among clinical isolates of M. tuberculosis, and the use of comparative genomics to understand the observed heterogeneity in susceptibility. Eighty-nine South African clinical isolates of varying first and second-line drug susceptibility patterns and two reference strains of M. tuberculosis underwent minimum inhibitory concentration (MIC) determination to two β-lactams: amoxicillin and meropenem, both alone and in combination with clavulanate, a β–lactamase inhibitor. 41/91 (45%) of tested isolates were found to be hypersusceptible to amoxicillin/clavulanate relative to reference strains, including 14/24 (58%) of multiple drug-resistant (MDR) and 22/38 (58%) of extensively drug-resistant (XDR) isolates. Genome-wide polymorphisms identified using whole-genome sequencing were used in a phylogenetically-aware linear mixed model to identify polymorphisms associated with amoxicillin/clavulanate susceptibility. Susceptibility to amoxicillin/clavulanate was over-represented among isolates within a specific clade (LAM4), in particular among XDR strains. Twelve sets of polymorphisms were identified as putative markers of amoxicillin/clavulanate susceptibility, five of which were confined solely to LAM4. Within the LAM4 clade, ‘paradoxical hypersusceptibility’ to amoxicillin/clavulanate has evolved in parallel to first and second-line drug resistance. Given the high prevalence of LAM4 among XDR TB in South Africa, our data support an expanded role for β-lactam/β-lactamase inhibitor combinations for treatment of drug-resistant M. tuberculosis. Elsevier 2016-06-01 /pmc/articles/PMC4972527/ /pubmed/27333036 http://dx.doi.org/10.1016/j.ebiom.2016.05.041 Text en © 2016 The Authors. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Cohen, Keira A.
El-Hay, Tal
Wyres, Kelly L.
Weissbrod, Omer
Munsamy, Vanisha
Yanover, Chen
Aharonov, Ranit
Shaham, Oded
Conway, Thomas C.
Goldschmidt, Yaara
Bishai, William R.
Pym, Alexander S.
Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title_full Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title_fullStr Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title_full_unstemmed Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title_short Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics
title_sort paradoxical hypersusceptibility of drug-resistant mycobacteriumtuberculosis to β-lactam antibiotics
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972527/
https://www.ncbi.nlm.nih.gov/pubmed/27333036
http://dx.doi.org/10.1016/j.ebiom.2016.05.041
work_keys_str_mv AT cohenkeiraa paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT elhaytal paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT wyreskellyl paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT weissbrodomer paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT munsamyvanisha paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT yanoverchen paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT aharonovranit paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT shahamoded paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT conwaythomasc paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT goldschmidtyaara paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT bishaiwilliamr paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics
AT pymalexanders paradoxicalhypersusceptibilityofdrugresistantmycobacteriumtuberculosistoblactamantibiotics